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The importance of understanding melanoma progres-
sion is emphasized by the adverse clinical outcomes of
most patients with advanced disease. Although the
malignant nature of melanoma cells is determined by
both genetic and epigenetic factors, considering the bio-
logical framework within which these factors develop
is critical to identifying and targeting them for clinical
benefit. If melanoma progresses according to a cancer
stem cell (CSC) model in which rare tumorigenic cells
not only renew their own malignant potential but also
produce bulk populations of cells that are rendered irre-
versibly non-tumorigenic, then the implications for
research and treatment of this disease would be pro-
found. For example, it may be difficult to identify molec-
ular drivers of tumorigenesis if tumorigenic cells are
rare and not studied separately from less ⁄ non-tumori-
genic melanoma cells that comprise most of the tumor.
Moreover, if tumorigenic potential is present in only a
small proportion of melanoma cells, then eliminating
these cells will be essential to eradicate disease in
patients. Because of this, much attention has been paid
to the question of whether melanoma progresses
according to a CSC model.
Over the last 5 yr, the pendulum of evidence has
swung for and against the possibility that melanoma
progresses according to a CSC model. Frank and col-
leagues tested the CSC model using classical in vivo
techniques and found that only one in a million mela-
noma cells had tumorigenic potential that was 10-fold
enriched in cells expressing the membrane transporter
molecule ABCB5 (Schatton et al., 2008). However,
using more permissive in vivo tumorigenesis assay con-
ditions, the Morrison laboratory subsequently identified
tumorigenic potential in a very high proportion (25%)
of melanoma cells (Quintana et al., 2008). Since that
study, Bosenberg and colleagues reported that tumori-
genic cells can comprise a high proportion of cells in
mouse melanomas (Held et al., 2010). These findings
indicate that the frequency of tumorigenic melanoma
cells had been previously underestimated by using
tumorigenesis assays that unexpectedly concealed
malignant potential in the vast majority of cells. It is criti-
cal in testing the cancer stem cell model to identify
assay conditions that are permissive for revealing
tumorigenic potential in cells (Shackleton and Quintana,
2010).
A recent study from the Weissman laboratory (Boiko
et al., 2010) encourages melanoma biologists to re-eval-
uate the question of whether melanoma follows a CSC
model. The central experiments of this paper that tested
the CSC model were performed by isolating phenotypi-
cally distinct melanoma cells from tumors and trans-
planting them into immunocompromised mice. For
tumors from which tumorigenesis by unfractionated
melanoma cells was studied (#213, #114 and #1119),
limiting dilution analysis (Hu and Smyth, 2009) of the
data presented in Supp Table 3 reveals that for all
tumors the frequency of tumorigenic cells was <0.05%.
This contrasts with the studies of malignant potential in
unfractionated human melanoma cells by Quintana et al.
(2008), in which the average frequency of tumorigenic
cells was 25% (Quintana et al., 2008; Fig 3c). As both
studies evaluated tumors that were at similar stages of
disease progression and that were obtained directly
from patients, these data suggest that Boiko et al.
(2010) used a tumorigenesis assay that was several
orders of magnitude less sensitive than the assay used
by Quintana et al. (2008).
Boiko et al. (2010) also found that cells expressing
CD271 (also known as nerve growth factor receptor or
p75) were significantly (P < 0.05) enriched in tumori-
genic potential in 5 ⁄ 6 of the melanomas studied directly
from patients, compared with CD271) cells. The finding
of CD271 as a putative human melanoma stem cell mar-
ker contrasts with the findings of Held et al. (2010),
who found that tumorigenic potential was enriched in
the CD271) fraction of mouse melanomas (Held et al.,
2010). In addition, studies in the Morrison laboratory of
melanoma cells obtained directly from multiple patients
and separated according to CD271 expression have
consistently grown tumors from transplants of low
numbers of CD271) cells, such that no enrichment of
tumorigenic activity in CD271+ melanoma cells has been
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observed (E. Quintana, M. Shackleton, S. Morrison,
unpublished).
The reasons for the contrasting results of Boiko et al.
(2010) and Quintana et al. (2008) are not clear. Both
studies evaluated melanomas at similar stages of
disease progression [compare Suppl. Table 2, ‘Sample
tissue type, location’ column, in Boiko et al. (2010)
versus Suppl. Table 1 in Quintana et al. (2008)], so
putative stage-related differences in tumor biology are
not likely to explain the effect. Additionally, although
Quintana et al. (2008) performed some experiments
using cells obtained from tumors that had first been
grown as xenografts in mice, the data were confirmed
in non-xenografted melanomas obtained directly from
six patients, including two primary cutaneous melano-
mas (Quintana et al., 2008; Fig 3c). The differences
between the studies cannot therefore be explained by
the use in Quintana et al. (2008) of cells only derived
from xenografted melanomas.
A more likely explanation is the different tumorigene-
sis assay conditions used by each group. Boiko et al.
(2010) used a one to three hour enzymatic digestion
protocol to isolate cells from tumors before mixing
sorted cells with standard Matrigel and transplanting
intradermally into Rag) ⁄ ) cc) ⁄ ) (RG) mice. Quintana
et al. (2008) used a much shorter (<30 min) digestion
protocol with a different composition of enzymes and
mixed sorted cells with high protein Matrigel before
transplanting subcutaneously into NOD ⁄ SCID IL2Rc) ⁄ )
(NSG) mice. Differences in tissue digestion methods
may result in differences in the viability of cells and thus
affect tumorigenic potential. Additionally, as the dermis
is composed of much denser connective tissue ele-
ments than subcutaneous tissue, it is conceivable that
intradermal injection may inhibit tumor formation by
melanoma cells that are tumorigenic after subcutaneous
injection. Also, it is possible that the host environment
of RG mice inhibits melanoma cell tumorigenicity in
unexpected ways, despite these mice lacking B-, T- and
NK cell function. Other differences between the tumori-
genesis assays used may also contribute to the con-
trasting data. Although it would be surprising if any
single assay variation explained the orders of magnitude
difference in efficiency of tumor formation seen in the
two studies, there can be large compounding effects of
multiple assay differences on the detection of tumori-
genic potential in human melanoma cells (Quintana
et al., 2008).
Dramatically different interpretations of tumor biology
can arise from seemingly minor differences in the detail
of how tumorigenesis assays are performed (Quintana
et al., 2008). If CD271) melanoma cells are non-tumori-
genic only under certain assay conditions, it will
be unwise to conclude that they do not contribute to
disease progression in patients. It will be critical for
other laboratories to test whether melanomas contain
common or rare tumorigenic cells and to determine
whether tumorigenic potential is restricted to phenotypi-
cally distinct cells that are hierarchically organized within
tumors and distinguished by expression of CD271,
ABCB5 or other markers. We encourage others to use
sensitive assays to address these questions thoroughly,
so that the full spectrum of cells with the potential to
propagate disease can be detected. It will also be
important to test carefully whether the contrasting find-
ings of Quintana et al. (2008) and Boiko et al. (2010) can
be explained by differences in the tumorigenesis assays
used.
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